Analyst Soumit Roy of JonesTrading maintained a Buy rating on Evaxion Biotech, retaining the price target of $10.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Soumit Roy has given his Buy rating due to a combination of factors that highlight Evaxion Biotech’s promising future prospects. One of the main reasons is the potential business development activities surrounding Evaxion’s EVX-01 and other pipeline assets. The anticipation of strategic partnerships or out-licensing agreements for EVX-01, a personalized cancer vaccine, is a significant factor. The vaccine’s unique approach, using AI-Immunology to identify neoantigens based on individual tumor profiles, adds to its appeal.
Additionally, there are two key catalysts expected in 2026 that could drive the company’s growth. The first is Merck’s decision on whether to in-license the infectious disease vaccine EVX-B2, which could result in substantial milestone payments for Evaxion. The second is the upcoming three-year follow-up data for EVX-01 in advanced melanoma, which has already shown promising clinical responses. These developments, along with the planned clinical development of EVX-04 in acute myeloid leukemia, underscore the company’s expanding pipeline and potential for future success.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $16.00 price target.